Michael P. Phalen Sells 15,835 Shares of Boston Scientific Corporation (BSX) Stock

Boston Scientific Corporation (NYSE:BSX) EVP Michael P. Phalen sold 15,835 shares of the business’s stock in a transaction that occurred on Saturday, December 29th. The shares were sold at an average price of $25.25, for a total value of $399,833.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Michael P. Phalen also recently made the following trade(s):

  • On Wednesday, November 29th, Michael P. Phalen sold 15,500 shares of Boston Scientific stock. The shares were sold at an average price of $26.66, for a total value of $413,230.00.
  • On Monday, October 30th, Michael P. Phalen sold 15,500 shares of Boston Scientific stock. The shares were sold at an average price of $28.42, for a total value of $440,510.00.

Shares of Boston Scientific Corporation (BSX) opened at $25.32 on Friday. The company has a current ratio of 0.72, a quick ratio of 0.50 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $35,098.89, a price-to-earnings ratio of 41.51, a price-to-earnings-growth ratio of 1.79 and a beta of 0.96. Boston Scientific Corporation has a twelve month low of $21.95 and a twelve month high of $29.93.

Boston Scientific (NYSE:BSX) last posted its earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.31. The company had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.21 billion. Boston Scientific had a return on equity of 23.60% and a net margin of 9.55%. Boston Scientific’s revenue was up 5.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.27 earnings per share. equities analysts forecast that Boston Scientific Corporation will post 1.25 EPS for the current year.

Institutional investors have recently bought and sold shares of the business. Wells Fargo & Company MN lifted its holdings in shares of Boston Scientific by 10.5% during the 2nd quarter. Wells Fargo & Company MN now owns 9,157,768 shares of the medical equipment provider’s stock valued at $253,854,000 after purchasing an additional 867,983 shares during the last quarter. Sit Investment Associates Inc. lifted its holdings in shares of Boston Scientific by 37.8% during the 3rd quarter. Sit Investment Associates Inc. now owns 141,710 shares of the medical equipment provider’s stock valued at $4,134,000 after purchasing an additional 38,855 shares during the last quarter. Greenwood Capital Associates LLC lifted its holdings in shares of Boston Scientific by 71.7% during the 3rd quarter. Greenwood Capital Associates LLC now owns 91,579 shares of the medical equipment provider’s stock valued at $2,671,000 after purchasing an additional 38,249 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. lifted its holdings in shares of Boston Scientific by 35,016.2% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 3,042,464 shares of the medical equipment provider’s stock valued at $84,337,000 after purchasing an additional 3,033,800 shares during the last quarter. Finally, Knights of Columbus Asset Advisors LLC lifted its holdings in shares of Boston Scientific by 94.9% during the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 38,600 shares of the medical equipment provider’s stock valued at $1,126,000 after purchasing an additional 18,800 shares during the last quarter. Institutional investors own 90.36% of the company’s stock.

A number of analysts recently issued reports on the company. Evercore ISI assumed coverage on Boston Scientific in a report on Wednesday. They issued an “in-line” rating and a $27.00 price target for the company. BMO Capital Markets reiterated a “buy” rating and issued a $32.00 price target on shares of Boston Scientific in a report on Tuesday, December 12th. TheStreet lowered Boston Scientific from a “b” rating to a “c+” rating in a report on Thursday, December 7th. Needham & Company LLC upgraded Boston Scientific from a “buy” rating to a “strong-buy” rating and boosted their price target for the company from $25.04 to $32.00 in a report on Friday, December 8th. Finally, SunTrust Banks set a $33.00 price target on Boston Scientific and gave the company a “buy” rating in a report on Monday, December 4th. One analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $30.94.

TRADEMARK VIOLATION NOTICE: This story was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.chaffeybreeze.com/2018/01/05/michael-p-phalen-sells-15835-shares-of-boston-scientific-corporation-bsx-stock.html.

About Boston Scientific

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Insider Buying and Selling by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply